Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors
Conditions
Interventions
pralatrexate
fluorouracil
+8 more
Locations
1
United States
University of Nebraska Medical Center, Eppley Cancer Center
Omaha, Nebraska, United States
Start Date
September 14, 2010
Primary Completion Date
February 4, 2015
Completion Date
June 1, 2017
Last Updated
December 26, 2023
NCT01137825
NCT02293954
NCT00483366
NCT00875004
NCT02088775
NCT00471432
Lead Sponsor
University of Nebraska
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions